BRAF V600E mutation-specific antibody: a review
LL Ritterhouse, JA Barletta - Seminars in diagnostic pathology, 2015 - Elsevier
The significance of BRAF mutations in neoplasia was first recognized in 2002 when
mutations were discovered in a broad range of cancers. Numerous subsequent studies …
mutations were discovered in a broad range of cancers. Numerous subsequent studies …
Diagnostic challenges during inflammation and cancer: current biomarkers and future perspectives in navigating through the minefield of reactive versus dysplastic …
In the setting of pronounced inflammation, changes in the epithelium may overlap with
neoplasia, often rendering it impossible to establish a diagnosis with certainty in daily …
neoplasia, often rendering it impossible to establish a diagnosis with certainty in daily …
The Presence of Typical “BRAFV600E-Like” Atypia in Papillary Thyroid Carcinoma is Highly Specific for the Presence of the BRAFV600E Mutation
J Turchini, L Sioson, A Clarkson, A Sheen… - Endocrine …, 2023 - Springer
Papillary thyroid carcinomas (PTCs) are driven by a variety of molecular abnormalities
including BRAF, RAS, ALK, RET, and NTRK alterations. PTCs driven by the BRAFV600E …
including BRAF, RAS, ALK, RET, and NTRK alterations. PTCs driven by the BRAFV600E …
Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population
RJ Gertz, Y Nikiforov, W Rehrauer… - … of pathology & …, 2016 - meridian.allenpress.com
Context Papillary thyroid carcinoma (PTC) is an uncommon tumor in the pediatric
population. A limited number of studies have examined genetic mutations affecting the …
population. A limited number of studies have examined genetic mutations affecting the …
Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach
Abstract Recently BRAF V600E mutant–specific antibody (clone VE1) became available to
immunohistochemically pinpoint the occurrence of these BRAF-mutant proteins in different …
immunohistochemically pinpoint the occurrence of these BRAF-mutant proteins in different …
Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta …
KG Parker, MG White, NA Cipriani - Head and neck pathology, 2020 - Springer
The evaluation of surgically resected papillary thyroid carcinomas (PTC) by
immunohistochemistry (IHC) for BRAF mutation has diagnostic, prognostic and therapeutic …
immunohistochemistry (IHC) for BRAF mutation has diagnostic, prognostic and therapeutic …
VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer
Detection of BRAF V600E is useful for making diagnosis and risk stratification of papillary
thyroid carcinoma (PTC). Molecular testing, however, is not always available for routine …
thyroid carcinoma (PTC). Molecular testing, however, is not always available for routine …
Papillary thyroid carcinoma with rare exon 15 BRAF mutation has indolent behavior: a single-institution experience
L Torregrossa, D Viola, E Sensi… - The Journal of …, 2016 - academic.oup.com
Context: Approximately 40% of papillary thyroid carcinomas (PTCs) harbor the BRAF V600E
mutation, which is significantly associated with the advanced clinicopathological features of …
mutation, which is significantly associated with the advanced clinicopathological features of …
Utility of the BRAF p. V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma
AL Smith, MD Williams, J Stewart… - Cancer …, 2018 - Wiley Online Library
BACKGROUND The identification of BRAF mutations in thyroid cancer has prognostic and
therapeutic implications. Although the gold standard for identifying BRAF mutations is …
therapeutic implications. Although the gold standard for identifying BRAF mutations is …
Association of combined PD‐L1 expression and tumour‐infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma
C Bence, V Hofman, E Chamorey… - Journal of the …, 2020 - Wiley Online Library
Background Recent advances obtained with immune checkpoint inhibitors (ICI s) targeting
the programmed cell death‐1 (PD‐1) protein have significantly improved the outcome of …
the programmed cell death‐1 (PD‐1) protein have significantly improved the outcome of …